Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial - PubMed
Ontario Institute for Cancer Research and London Regional Cancer Program Catalyst Grant.